Literature DB >> 34259322

Neoadjuvant immunochemotherapy in surgically resectable non-small-cell lung cancer: surgical expertise required.

David R Jones1,2.   

Abstract

Entities:  

Keywords:  Immune checkpoint inhibitors; Neoadjuvant; Non-small-cell lung cancer

Mesh：

Year:  2021        PMID： 34259322      PMCID： PMC8278351          DOI： 10.1093/ejcts/ezab070

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN： 1010-7940            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

Authors:  Catherine A Shu; Justin F Gainor; Mark M Awad; Codruta Chiuzan; Claud M Grigg; Aliyah Pabani; Robert F Garofano; Mark B Stoopler; Simon K Cheng; Abby White; Michael Lanuti; Frank D'Ovidio; Matthew Bacchetta; Joshua R Sonett; Anjali Saqi; Naiyer A Rizvi
Journal:  Lancet Oncol       Date:  2020-05-07       Impact factor: 41.316

4.  The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer.

Authors:  John G Edwards; Kari Chansky; Paul Van Schil; Andrew G Nicholson; Souheil Boubia; Elisabeth Brambilla; Jessica Donington; Françoise Galateau-Sallé; Hans Hoffmann; Maurizio Infante; Mirella Marino; Edith M Marom; Jun Nakajima; Marcin Ostrowski; William D Travis; Ming-Sound Tsao; Yasushi Yatabe; Dorothy J Giroux; Lynn Shemanski; John Crowley; Marc Krasnik; Hisao Asamura; Ramón Rami-Porta
Journal:  J Thorac Oncol       Date:  2019-11-13       Impact factor: 15.609

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Raymond U Osarogiagbon
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777
  7 in total
  1 in total

1.  Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis-A Case Series of Three Patients.

Authors:  Agnes Koch; Stefan Sponholz; Stephan Trainer; Jan Stratmann; Martin Sebastian; Maximilian Rauch; Robert Wolff; Joachim P Steinbach; Michael W Ronellenfitsch; Hans Urban
Journal:  Curr Oncol       Date:  2022-03-23       Impact factor: 3.109
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.